hexadecyl 4-iodobenzoate | 70152-94-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: hexadecyl 4-iodobenzoate
• 英文别名: n-Hexadecyl-p-iodobenzoat；Hexadecyl-p-iodbenzoat；Hexadecyl-4-iodobenzoate
• CAS: 70152-94-2
• 化学式: C₂₃H₃₇IO₂
• 分子量: 472.45
• InChiKey: ZKFRNBNJQLIUAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.7
• 重原子数：
  26
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  hexadecyl 4-iodobenzoate 、 六正丁基二锡 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 反应 8.0h， 以71%的产率得到hexadecyl 4-tributylstannylbenzoate
  参考文献：
  名称：

  Vivid Tumor Imaging Utilizing Liposome-Carried Bimodal Radiotracer

  摘要：

  By developing a new bimodal radioactive tracer that emits both luminescence and nuclear signals, a trimodal liposome for optical, nuclear, and magnetic resonance imaging is efficiently prepared. Fast clearance of the radiotracer from reticuloendothelial systems enables vivid tumor imaging with minimum background.

  DOI：

  10.1021/ml400513g
• 作为产物：
  描述：

  1-十六烷醇 、 4-碘苯甲酰氯 在 吡啶 作用下， 生成 hexadecyl 4-iodobenzoate
  参考文献：
  名称：

  Remote functionalization reactions as conformational probes for flexible alkyl chains

  摘要：

  DOI：

  10.1021/ja00472a030

文献信息

• Development and application of tumor diagnostic radioactive probe targeting folic acid receptor
  申请人：Kyungpook National University Industry-Academic Cooperation Foundation

  公开号：US11266755B2

  公开（公告）日：2022-03-08

  The present invention pertains to a novel liposome-based contrast agent that is for suppressing absorption in the reticuloendothelial system and for tumor-specific delivery of a radiolabeled substance. More specifically, the present invention pertains to: a liposome contrast agent containing a lipid and a compound of chemical formula 1, which is a radiolabeled substance, the liposome contrast agent being characterized in that the lipid is composed of (a) cholesterol, (b) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and (c) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy(polyethylene glycol)-2000] (DSPE-PEG2000); and a cancer diagnostic composition containing the liposome contrast agent as an active ingredient. If a liposome system, containing a contrast substance of chemical formula 1 having a unique lipid composition provided by the present invention, is manufactured, the tumor-to-organ uptake ratio of the contrast substance in the reticuloendothelial system increases significantly, thus greatly increasing the tumor diagnostic efficiency of the compound of chemical formula 1.

  本发明涉及一种新型脂质体造影剂，它可抑制网状内皮系统的吸收，并可用于肿瘤特异性递送放射性标记物质。更具体地说，本发明涉及一种脂质体造影剂，含有一种脂质和一种化学式 1 的化合物，该化合物是一种放射性标记物质，该脂质体造影剂的特征在于该脂质由(a)胆固醇、(b)1,2-二棕榈酰-sn-甘油-3-磷酸胆碱（DPPC）和(c)1,2-二硬脂酰-sn-甘油-3-磷酸乙醇胺-N [甲氧基（聚乙二醇）-2000]（DSPE-PEG2000）组成；以及含有脂质体造影剂作为活性成分的癌症诊断组合物。如果制造出含有本发明提供的具有独特脂质成分的化学式 1 造影剂的脂质体系统，造影剂在网状内皮系统中的肿瘤器官吸收比就会显著增加，从而大大提高化学式 1 化合物的肿瘤诊断效率。
• DEVELOPMENT AND APPLICATION OF TUMOR DIAGNOSTIC RADIOACTIVE PROBE TARGETING FOLIC ACID RECEPTOR
  申请人：Kyungpook National University Industry-Academic Cooperation Foundation

  公开号：US20200101179A1

  公开（公告）日：2020-04-02

  The present invention pertains to a novel liposome-based contrast agent that is for suppressing absorption in the reticuloendothelial system and for tumor-specific delivery of a radiolabeled substance. More specifically, the present invention pertains to: a liposome contrast agent containing a lipid and a compound of chemical formula 1, which is a radiolabeled substance, the liposome contrast agent being characterized in that the lipid is composed of (a) cholesterol, (b) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and (c) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy(polyethylene glycol)-2000] (DSPE-PEG2000); and a cancer diagnostic composition containing the liposome contrast agent as an active ingredient. If a liposome system, containing a contrast substance of chemical formula 1 having a unique lipid composition provided by the present invention, is manufactured, the tumor-to-organ uptake ratio of the contrast substance in the reticuloendothelial system increases significantly, thus greatly increasing the tumor diagnostic efficiency of the compound of chemical formula 1.
• [EN] RADIOACTIVE CELL MARKER<br/>[FR] MARQUEUR CELLULAIRE RADIOACTIF
  申请人：KYUNGPOOK NAT UNIV IND ACAD

  公开号：WO2010074532A9

  公开（公告）日：2010-11-04

  [EN] The present invention relates to the radioactive marker compound of chemical formula 1 or 2, a composition containing the radioactive marker compound, and a method for preparing the radioactive marker compound. The marker compound of the invention enables cells to be marked with high efficiency and the movements of a marked cell to be monitored over a long period.
  [FR] La présente invention concerne un composé de marquage radioactif de formule chimique (1) ou (2), une composition contenant ce composé de marquage radioactif et un procédé de préparation dudit composé de marquage radioactif. Le composé de marquage de l'invention permet de marquer des cellules avec une haute efficacité et de surveiller les mouvements d'une cellule marquée pendant une longue période.